Indeed, Nuance Matters.
作者信息
Dresler Carolyn, Warren Graham W, Arenberg Douglas, Yang Ping, Steliga Matthew A, Cummings K Michael, Stone Emily, Jassem Jacek
机构信息
International Association for the Study of Lung Cancer, Montrose, Colorado.
Department of Radiation Oncology, Medical University of South Carolina, Charleston South Carolina; Department of Cell and Molecular, Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston South Carolina.
出版信息
J Thorac Oncol. 2019 Jan;14(1):e16-e17. doi: 10.1016/j.jtho.2018.11.004.
PMID:30579550
Abstract
摘要
相似文献
1
Indeed, Nuance Matters.
J Thorac Oncol. 2019 Jan;14(1):e16-e17. doi: 10.1016/j.jtho.2018.11.004.
2
Nuance Matters.
J Thorac Oncol. 2019 Jan;14(1):e15. doi: 10.1016/j.jtho.2018.08.2037.
3
"Teachable Moment" Interventions in Lung Cancer: Why Action Matters.
J Thorac Oncol. 2018 May;13(5):603-605. doi: 10.1016/j.jtho.2018.02.020.
4
Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Lancet Oncol. 2016 Dec;17(12):1627-1628. doi: 10.1016/S1470-2045(16)30567-8. Epub 2016 Nov 8.
5
[Notable adverse events of ALK inhibitors in patients with ALK rearranged non-small-cell lung cancer].
Nihon Rinsho. 2015 Feb;73 Suppl 2:256-60.
6
Sequential Use of ALK Inhibitors: An Optional Approach.
J Thorac Oncol. 2016 Dec;11(12):e153-e154. doi: 10.1016/j.jtho.2016.10.005.
7
ALK inhibitors: plateauing systemic and intracranial activity?
Lancet Oncol. 2016 Apr;17(4):404-406. doi: 10.1016/S1470-2045(16)00025-5. Epub 2016 Mar 11.
8
Crizotinib in ALK-positive lung cancer.
Lancet Oncol. 2012 Oct;13(10):962-3. doi: 10.1016/S1470-2045(12)70375-3. Epub 2012 Sep 4.
9
Ascending role of next-generation ALK inhibitors.
Lancet Oncol. 2017 Jul;18(7):837-839. doi: 10.1016/S1470-2045(17)30338-8. Epub 2017 Jun 9.
10
Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.
J Thorac Oncol. 2017 May;12(5):e49-e51. doi: 10.1016/j.jtho.2017.01.009.
Zotero 插件